Plasma cell-free RNA PD-L1 expression and survival with immune checkpoint inhibitor-based treatment in advanced non-small-cell lung cancer

被引：0
|
作者：
Walker, Paul R. [1 ]
Jayananda, Sriraksha [1 ]
Pasli, Melisa [1 ]
Muzaffar, Mahvish [1 ]
机构：
[1] East Carolina Univ, Brody Sch Med, Greenville, NC 27858 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21090
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer
    Igawa, Satoshi
    Sato, Yuichi
    Ryuge, Shinichiro
    Ichinoe, Masaaki
    Katono, Ken
    Hiyoshi, Yasuhiro
    Otani, Sakiko
    Nagashio, Ryo
    Nakashima, Hiroyasu
    Katagiri, Masato
    Sasaki, Jiichiro
    Murakumo, Yoshiki
    Satoh, Yukitoshi
    Masuda, Noriyuki
    ONCOLOGY, 2017, 92 (05) : 283 - 290
  • [42] The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer
    Zhao, Jing
    Wu, Yang
    Yue, Yuan
    Chen, Minjiang
    Xu, Yan
    Liu, Xiangning
    Liu, Xiaoyan
    Gao, Xiaoxing
    Wang, Hanping
    Si, Xiaoyan
    Zhong, Wei
    Zhang, Xiaotong
    Zhang, Li
    Wang, Mengzhao
    THORACIC CANCER, 2023, 14 (05) : 497 - 505
  • [43] PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
    Jing, Wang
    Li, Miaomiao
    Zhang, Yan
    Teng, Feifei
    Han, Anqin
    Kong, Li
    Zhu, Hui
    ONCOTARGETS AND THERAPY, 2016, 9 : 489 - 502
  • [44] Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia
    Cheng, Ying
    Yang, James Chih-Hsin
    Okamoto, Isamu
    Zhang, Li
    Hu, Jie
    Wang, Donglin
    Hu, Chengping
    Zhou, Jianying
    Wu, Lin
    Cao, Lejie
    Liu, Jiwei
    Zhang, Helong
    Sun, Hong
    Wang, Ziping
    Gao, Hongjun
    Yan, Yan
    Xiao, Suijun
    Lin, Jianxin
    Pietanza, M. Catherine
    Kurata, Takayasu
    IMMUNOTHERAPY, 2023, 15 (13) : 1029 - 1044
  • [45] Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
    Olivier Bylicki
    Nicolas Paleiron
    Jacques Margery
    Florian Guisier
    Alain Vergnenegre
    Gilles Robinet
    Jean-Bernard Auliac
    Radj Gervais
    Christos Chouaid
    Targeted Oncology, 2017, 12 : 563 - 569
  • [46] Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
    Oya, Yuko
    Kuroda, Hiroaki
    Nakada, Takeo
    Takahashi, Yusuke
    Sakakura, Noriaki
    Hida, Toyoaki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)
  • [47] Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
    Bylicki, Olivier
    Paleiron, Nicolas
    Margery, Jacques
    Guisier, Florian
    Vergnenegre, Alain
    Robinet, Gilles
    Auliac, Jean-Bernard
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2017, 12 (05) : 563 - 569
  • [48] PD-L1 as a predictive factor for non-small-cell lung cancer prognosis
    Chen, Long
    Zhu, Xian-Ze
    Zhao, Shi-Jie
    Yang, Qiang-Wei
    LANCET ONCOLOGY, 2024, 25 (06): : e233 - e233
  • [49] PD-L1 in non-small-cell lung cancer: the third target for immunotherapy
    Smit, Egbert F.
    van den Heuvel, Michel M.
    LANCET, 2016, 387 (10030): : 1795 - 1796
  • [50] Comparison of PD-L1 immunohistochemistry assays for non-small-cell lung cancer
    Hong, Goohyeon
    Kim, Youn Seup
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
12345